Medical devices, healthcare technology and the business of care
PMA approval · P000025

COMBI 40+ COCHLEAR IMPLANT SYSTEM

Med-El Corp. · Decision date Aug 20, 2001

FDA DECISIONP000025

What did the FDA approve?

FDA records P000025 as an original PMA application. The recorded decision is approval, dated Aug 20, 2001.

FDA approval order statement

APPROVAL FOR THE MED-EL COMBI 40+ COCHLEAR IMPLANT SYSTEM (COMBI 40+). THE DEVICE IS INTENDED TO PROVIDE THE OPPORTUNITY TO DETECT AND RECOGNIZE AUDITORY INFORMATION THROUGH ELECTRICAL STIMULATION OF THE AUDITORY NERVE FOR SERVER TO PROFOUNDLY HEARING-IMPAIRED INDIVIDUALS WHO OBTAIN LITTLE OR NO BENEFIT FROM CONVENTIONAL ACOUSTIC AMPLIFICATION IN THE BEST-AIDED CONDITION. THE COMBI 40+ IS INDICATED FOR THE FOLLOWING PATIENT POPULATIONS: ADULTS OF EIGHTEEN (18) YEARS OF AGE OR OLDER WHO HAVE BILATERAL, SENSORINEURAL HEARING IMPAIRMENT AND OBTAIN LIMITED BENEFIT FROM APPROPRIATELY FITTED BINAURAL HEARING AIDS. THESE INDIVIDUALS TYPICALLY DEMONSTRATE BILATERAL SEVERE TO PROFOUND SENSORINEURAL HEARING LOSS DETERMINED BY A PURE TONE AVERAGE OF 70 DB OR GREATER AT 500 HZ, 1000 HZ, AND 2000 HZ. LIMITED BENEFIT FROM AMPLIFICATION IS DEFINED BY TEST SCORES OF 40% CORRECT OR LESS IN BEST-AIDED LISTENING CONDITION ON CD RECORDED TESTS OF OPEN-SET SENTENCE RECOGNITION HEARING IN NOISE TEST (HINT) SENTENCES. CHILDREN AGED EIGHTEEN (18) MONTHS TO SEVENTEEN (17) YEARS ELEVEN (11) MONTHS MUST DEMONSTRATE A PROFOUND, BILATERAL SENSORINEURAL HEARING LOSS WITH THRESHOLDS OF 90 DB OR GREATER AT 1000HZ. IN YOUNGER CHILDREN, LITTLE OR NO BENEFIT IS DEFINED BY LACK OF PROGRESS IN THE DEVELOPMENT OF SIMPLE AUDITORY SKILLS IN CONJUNCTION WITH APPROPRIATE AMPLIFICATION AND PARTICIPATION IN INTENSIVE AURAL HABILITATION OVER A THREE (3) TO SIX (6) MONTH PERIOD. IN OLDER CHILDREN, LACK OF AIDED BENEFIT IS DEFINED AS < 20% CORRECT ON THE MULTI-SYLLABIC LEXICAL NEIGHBORHOOD TEST (MLNT) OR LEXICAL NEIGHBORHOOD TEST (LNT), DEPENDING UPON THE CHILD'S COGNITIVE ABILITY AND LINGUISTIC SKILLS. A THREE (3) TO SIX (6) MONTH HEARING AID TRIAL IS REQUIRED FOR CHILDREN WITHOUT PREVIOUS EXPERIENCE WITH HEARING AIDS. RADIOLOGICAL EVIDENCE OF COCHLEAR OSSIFICATION MAY JUSTIFY A SHORTER TRIAL WITH AMPLIFICATION.
Regulatory pathway
Original PMA
Clinical specialty
Ear, Nose, Throat
Decision date
Aug 20, 2001

FDA source record

Regulatory record facts

Identifier
P000025
Regulatory pathway
Premarket approval application
Applicant
Med-El Corp.
Product code
MCM
Decision code
APPR
Decision date
Aug 20, 2001
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, cochlear.

Applicant
Med-El Corp.
Product code
MCM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P000025 received

    Application receipt date recorded by FDA.

  2. P000025 · FDA decision

    APPR

  3. P000025/S136 · Related supplement

    MED-EL Cochlear Implant System

Timeline entries are records held by MedtechLedger for P000025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000025

Product / regulatory recordCompanyPathwayDecision dateSource
Med-El Corp.PMA supplementOct 9, 2026FDA

Explore the linked device profile

Other records with product code MCM

Product / regulatory recordCompanyPathwayDecision dateSource
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Cochlear AmericasPMA supplementSep 28, 2026FDA
Advanced BionicsPMA supplementSep 18, 2026FDA
Advanced BionicsPMA supplementSep 4, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Med-El Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Furstenweg 77a, Innsbruck, 6020

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records